Ostrum Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ostrum Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-918	Closed	-$224K	–	583
2025 Q1	$224K	Sell	918 -23	-2%	-$6.92K	0.01%	493
2024 Q4	$309K	Sell	941 -3,314	-78%	-$1.12M	0.03%	456
2024 Q3	$1.42M	Buy	4,255 +1,779	+72%	+$565K	0.12%	259
2024 Q2	$676K	Sell	2,476 -193	-7%	-$56.1K	0.06%	355
2024 Q1	$923K	Hold	2,669	–	–	0.07%	358
2023 Q4	$862K	Buy	2,669 +11	+0.4%	+$3.45K	0.07%	344
2023 Q3	$953K	Sell	2,658 -18	-0.7%	-$6.95K	0.09%	324
2023 Q2	$1.01M	Buy	2,676 +3	+0.1%	+$1.22K	0.09%	314
2023 Q1	$1.28M	Buy	+2,673	New	+$1.25M	0.11%	250

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Ostrum Asset Management's BIO Position: Q2 2025 in Review

Ostrum Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 918 shares — an estimated $224K sold.

Ostrum Asset Management first reported a position in BIO in Q1 2023 and held it in 9 quarters. The position peaked at $1.42M in Q3 2024. 383 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Ostrum Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Ostrum Asset Management sold 918 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $224K.
Ostrum Asset Management first reported a position in Bio-Rad Laboratories Class A in Q1 2023 and held it in 9 quarters.
Ostrum Asset Management's Bio-Rad Laboratories Class A position peaked at $1.42M in Q3 2024.
383 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Ostrum Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.